Seagen Inc

NASDAQ:SGEN   3:59:59 PM EDT
144.44
+1.42 (+0.99%)
Products

U.S. FDA Grants Regular Approval And Expands Indication For PADCEV (Enfortumab Vedotin-Ejfv) For Patients With Locally Advanced Or Metastatic Urothelial Cancer

Published: 07/09/2021 20:05 GMT
Seagen Inc (SGEN) - U.S. FDA Grants Regular Approval and Expands Indication for Padcev® (enfortumab Vedotin-ejfv) for Patients With Locally Advanced Or Metastatic Urothelial Cancer.